Table 5. EORTC-RECIST and PERCIST criteria for evaluation of tumor response.

EORTC-RECIST

CR: non-measurable disease, disappearance of all known disease, confirmed at ≥4 wk

PR: estimated decrease of ≥50%, confirmed at 4 wk

PD: estimated increase of ≥25% in existent lesions

NC: neither PR nor PD criteria met

PERCIST

CMR: disappearance of all 18F-FDG-avid lesions

PMR: significant reduction in SUV in tumors

PMD: unequivocal progression of 18F-FDG-avid non-target lesions or appearance of new 18F-FDG-avid lesions typical of cancer

SMD: no visible change in metabolic activity of tumors

CMR, complete metabolic response; PMR, partial metabolic response; PD, progressive disease; SMD, stable metabolic disease; PMD, progressive metabolic disease; CR, complete remission; PR, partial remission; NC, no change; EORTC-RECIST, Research and Treatment of Cancer Response Evaluation Criteria In Solid Tumors; PERCIST, Response Criteria in Solid Tumors.